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Purpose: The prevalence of myopia is increasing around the world, stimulating interest in methods to slow its
progression. The primary justification for slowing myopia progression is to reduce the risk of vision loss through
sight-threatening ocular pathologic features in later life. The article analyzes whether the potential benefits of
slowing myopia progression by 1 diopter (D) justify the potential risks associated with treatments.
Methods: First, the known risks associated with various methods of myopia control are summarized, with
emphasis on contact lens wear. Based on available data, the risk of visual impairment and predicted years of
visual impairment are estimated for a range of incidence levels. Next, the increased risk of potentially sight-
threatening conditions associated with different levels of myopia are reviewed. Finally, a model of the risk of
visual impairment as a function of myopia level is developed, and the years of visual impairment associated with
various levels of myopia and the years of visual impairment that could be prevented with achievable levels of
myopia control are estimated.
Results: Assuming an incidence of microbial keratitis between 1 and 25 per 10 000 patient-years and that
15% of cases result in vision loss leads to the conclusion that between 38 and 945 patients need to be exposed
to 5 years of wear to produce 5 years of vision loss. Each additional 1 D of myopia is associated with a 58%, 20%,
21%, and 30% increase in the risk of myopic maculopathy, open-angle glaucoma, posterior subcapsular cata-
ract, and retinal detachment, respectively. The predicted mean years of visual impairment ranges from 4.42 in a
person with myopia of e3 D to 9.56 in a person with myopia of e8 D, and a 1-D reduction would lower these by
0.74 and 1.21 years, respectively.
Conclusions: The potential benefits of myopia control outweigh the risks: the number needed to treat to
prevent 5 years of visual impairment is between 4.1 and 6.8, whereas fewer than 1 in 38 will experience a loss of
vision as a result of myopia control. Ophthalmology 2021;-:1e19 ª 2021 by the American Academy of Ophthal-
mology. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Compelling evidence exists that myopia prevalence is
increasing worldwide. The global prevalence is projected to
reach 50% by the year 2050 in the absence of effective inter-
vention measures.1 The rising prevalence of myopia is also
accompanied by earlier onset, which in turn leads to an
increased risk of high myopia.2e4 Increased prevalence of
myopia, in particular high myopia, in turn leads to increased
visual impairment resulting from conditions associated with
myopia.5e7 Indeed, myopic maculopathy, also known as
myopic macular degeneration, is an increasing cause of visual
impairment.6,8 The onset of myopic maculopathy is earlier
than other major causes of visual impairment, occurring as
early as the fifth decade of life,9 so the years of impairment
commensurately are greater than later-onset conditions,
including age-related macular degeneration (AMD).10,11 In
both Europe and China, visual impairment resulting from
myopic maculopathy is more common than visual loss
resulting from diabetic eye disease.12e14
These factors have stimulated interest in methods to slow
myopia progression, with a number of therapies, including
topical atropine, spectacle lenses, dual-focus contact lenses,
multifocal soft contact lenses, and overnight orthokeratology,
showing clinically meaningful slowing of progression.15e18
The preferred method varies with country and by profes-
sion.19,20 Regulatory approval can also play a role, althoughª 2021 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.most myopia control in the United States is performed off-
label because only 1 device is approved for this indication.
The influence of behavioral modifications, such as increased
time outdoors and reduced screen time, on progression rate is
less clear.21,22
However, varying opinions exist regarding myopia control.
Advocates for myopia control assert that not offering myopia
control is unethical, and some clinical trials have moved chil-
drenout of the placebo armand into the treatment because of the
significant treatment benefits.23,24 In contrast, some
professional organizations such as the College of
Optometrists in the United Kingdom express caution, stating
that “not enough evidence [exists] to support the widespread
roll out of myopia control.”25 In addition, some clinicians
believe that the increased potential risk of serious ocular
infections argue against prescribing contact lenses to children.
Other organizations are paying attention to issues related to
myopia control. The American Academy of Ophthalmology,
for example, has published 2 Ophthalmic Technology
Assessments related to myopia control in recent years,26,27
having previously reviewed the safety of 1 approach,28 and
includes prevention of myopia progression in its Refractive
Errors and Refractive Surgery Preferred Practice Pattern.29
In a thoughtful editorial, Modjtahedi et al30 emphasize
the need to increase awareness about the increasing1https://doi.org/10.1016/j.ophtha.2021.04.032
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accurately stratify patient risk should be a significant focus
for future research endeavors” and that “it is essential for
ophthalmologists to work with optometrists, who are
frontline providers, to determine a collaborative frame
work and referral patterns to prevent myopic progression,
educate patients on the risks of myopia, and proactively
address associated pathology to serve the best interest of
our patients.” The University of Houston Institutional
Review Board determined that approval was not required.
All research adhered to the tenets of the Declaration of
Helsinki. This is a retrospective study using de-
identifiedsubject details. Informed consent was not obtained.
Methodologic Considerations in Risk-to-
Benefit Analysis of Myopia Treatment
These varying perspectives point to the central question that
this articles addresses: Do the potential benefits of reducing
myopia progression with interventions such contact lenses or
pharmaceutical options justify the potential risks associated
with those treatments? The primary justification for reducing
myopia progression is to reduce the risk of vision loss
through sight-threatening ocular pathologic features in later
life. Therefore, myopia is being managed because it is a risk
factor for visual impairment. The risk-to-benefit analysis of
any treatment can be considered on a population or an indi-
vidual basis. Not every patient with a risk factor for a con-
dition will go on to demonstrate the condition, so a number of
patients will be treated to avoid 1 adverse outcome, be it
onset of disease or visual impairment. The parameter, number
needed to treat (NNT), is used widely in health assessments
and is the reciprocal of the absolute risk reduction (ARR). For
example, in the Ocular Hypertension Treatment Study,31 the
5-year cumulative probability of glaucoma developing was
9.5% and 4.4% in untreated and treated patients, respectively.
Thus, the ARR is 5.1% (¼ 9.5e 4.4) and the NNT is 19.6 (¼
1 / 0.051). In other words, 20 patients need to be treated for 5
years to prevent 1 case of glaucoma. The ARR and NNT can
be balanced by the corresponding parameters: the absolute
risk increase, which is the risk associated with complications
of the treatment, and the number needed to harm (NNH),
which is the number of patients who need to be treated to
induce a single adverse event. The NNH is the reciprocal of
absolute risk increase.
Slowing myopia progression by 1 diopter (D) offers the
prospect of leaving amyope ate3Dwith treatment rather than
e4 D, or achieving a final refraction of e7 D with treatment
rather thane8 D. On the basis of existing data, both outcomes
offer potential benefits, but the ARR is much greater in those
with highmyopia because of the higher prevalence of myopia-
related vision impairment (and the NNT is lower) in those with
highermyopia. Although theNNTwill be greater in thosewith
lower myopia, they far outnumber those with higher myopia,
even in populations with a high prevalence.1 The values of
NNT and ARR are a function of the effectiveness of a
myopia intervention, regardless of the treatment, and the
level of myopia at the start of treatment. In contrast, the
values of NNH and absolute risk increase related to the
specific method of treatment and are largely independent of2
the level of myopia. Therefore, the risk-to-benefit assessment
of myopia treatment must consider all these elements, that is,
the effectiveness of an intervention in slowing down myopia
progression, risk of vision impairment associatedwithmyopia,
level of myopia, and treatment-specific risks. A final consid-
eration is that complications of myopia treatment may occur
many decades before anymyopia-associated visual loss, so the
duration in years of any treatment-associated complications
affecting vision may greatly exceed the duration of vision loss
attributable to myopia later in life.
To answer the central question of whether the benefits of
active myopia control justify the risks, this review first
summarizes the known risks associated with various
methods of myopia control, with an emphasis on contact
lens wear. Based on available data, the risk of visual
impairment and predicted years of visual impairment are
estimated for a range of incidence levels. Next, the increased
risk of potentially sight-threatening conditions associated
with different levels of myopia is reviewed. Finally, a model
of the risk of visual impairment as a function of myopia
level and age is developed, and the years of visual impair-
ment associated with various degrees of myopia and the
years of visual impairment that could be prevented with
achievable levels of myopia control are estimated.
Risks and Side Effects of Myopia Control
At the time of this review, 3 commonly used myopia control
therapies are in use: spectacles, atropine, and contact lenses.
Spectacles
Myopia control with spectacles has a 60-year history,
including bifocals,32e34 progressive addition lenses,35e37 and,
most recently, novel optical designs.38 In the United States,
children are prescribed polycarbonate spectacle lenses and
the minimal physical risks associated with these devices are
not increased by the incorporation of a multifocal correction
or other designs. Spectacle wear is associated with bicycle
crashes in children, although no association exists between
myopia or habitual visual acuity and bicycle crashes.39 The
study authors thus attribute the increased risk to a
“decrement in the peripheral visual field, thus reducing rider
awareness of oncoming vehicles and road obstacles.” Of
course, correcting myopia and eliminating blurred vision has
its own benefits. Some spectacle-based myopia treatments
incorporating positive dioptric power will be expected to have
modest effects on peripheral vision, and it is important that this
be quantified.40 Also, evidence exists that in the elderly,
multifocal and bifocal spectacles can increase the risk of
falls.41e43 Progressive addition lens and bifocal wearers are
twice as likely to fall as nonmultifocal wearers,43 although no
evidence suggests that the same risks apply in children,
perhaps because they rarely wear such lenses.
Atropine
Atropine is an antimuscarinic agent that causes pupil dilation
and loss of accommodation, even in concentrations as low as
0.01%.24,44 The associated symptoms of photophobia and near
vision difficulties vary, as expected, with concentration. This
Bullimore et al  Risks and Benefits of Myopia Controlcan be mitigated by photochromic lenses, multifocal lenses, or
both. In the Atropine for the Treatment of Myopia 2 Study,
among children receiving 0.5%, 0.1%, and 0.01% atropine,
70%, 61%, and 6%, respectively, requested combined
photochromic progressive addition spectacles, whereas the
remainder chose single-vision photochromic spectacles.44 In
the Low-Concentration Atropine for Myopia Progression
Study, the need for photochromic or progressive addition
lenses did not vary with atropine concentration among the
more than 400 children randomized to 0.01%, 0.025%, or
0.05% atropine or placebo.24 Between 30% and 40% of
children needed photochromic spectacles in all groups,
including the placebo group. Furthermore, 4 children needed
progressive addition spectacles, including 1 in the placebo
group. The most common ocular side effect in the
aforementioned clinical trials was allergic conjunctivitis,
which occurred in 3% to 7% of children in each arm,
including those receiving placebo in the Low-Concentration
Atropine for Myopia Progression Study, suggesting that the
preservative or other excipient in the solution may be the
causative agent.
With any topically applied drug, a risk of systemic ab-
sorption exists. The systemic effects of atropine are well
documented and include dryness of skin, mouth, and throat
resulting from decreased mucous membrane secretion;
restlessness, irritability, or delirium owing to central nervous
system stimulation; tachycardia; and flushed facial skin
resulting from its nonselective antimuscarinic properties.45
Despite atropine’s use in a large number of clinical trials
for myopia control24,44,46 and for penalization therapy for
amblyopia47e50 involving hundreds of children, no reports
exist of systemic adverse events related to topical atropine.
The Ophthalmic Technology Assessment on Atropine for
the Prevention of Myopia Progression in Children by the
American Academy of Ophthalmology does not list any
safety concerns.26 The review does not discuss the risks
associated with increased retinal light levels and AMD
with atropine-induced mydriasis, but this remains a theo-
retical possibility, although the dilation with low concen-
trations is modest, along with its impact on any long-term
cumulative dose, and may be offset by sunglasses. This
theoretical risk is mitigated partly because myopia is a
protective risk factor for AMD,51e53 possibly by the
reduced light flux density that results from a longer eye.54
Also, potential concerns exist because of premature
presbyopia induced by prolonged partial cycloplegia, but
we are only aware of anecdotal reports. A 7-year review
of atropine in Taiwan, where atropine has been used for
several decades, did not include any data on side effects.55
This is clearly an area where further data are required. In
summary, the risk of vision loss associated with topical
atropine, particularly lower concentrations, would seem to
be very low, but the prescription of photochromic
spectacles or soft contact lenses may be required at higher
concentrations.
Soft Contact Lenses
The complications associated with soft contact lens wear
have been well documented. Noninfectious inflammatoryevents may involve the cornea, conjunctiva, and periorbital
tissues. Those affecting the cornea are termed collectively
corneal infiltrative events; include infiltrative keratitis,
contact lens-associated red eye, and contact lens peripheral
ulcers; and occur at rates between 300 and 400 per 10 000
patient-years in adults.56e58 These are not considered to be
sight threatening and are managed by temporarily dis-
continuing contact lens wear, with the possible addition of a
topical prophylactic antibiotic. Microbial keratitis is less
common, with an incidence of approximately 20 per 10 000
patient-years in adults wearing lenses on an overnight basis,
but only between 2 and 4 per 10 000 patient-years for daily-
wear patients. Major studies of the incidence of microbial
keratitis associated with soft contact lenses are summarized
in Table 1.59e66 Regardless of the incidence, 15% or fewer
of cases of microbial keratitis result in vision loss.61,64e66
With respect to soft contact lenses for myopia control, 3
important variables influence the risk of corneal infiltrative
events and microbial keratitis: storage, material, and patient
age. First, many contact lenses designed for myopia control,
although not all, are prescribed using a daily disposable
replacement schedule.23 The benefits of eliminating contact
lens storage as a risk factor cannot be understated. For
example, Stapleton et al67 found that the risk of moderate
and severe microbial keratitis in daily wear contact lens
users was increased 6.4 times by poor storage case hygiene
and 5.4 times by infrequent storage case replacement. The
authors note the previously reported associations between
solution type and more severe disease for Acanthamoeba
and Fusarium keratitis.68e70 Again, these risks can be
reduced substantially with daily disposable lenses. Second,
contact lens material can also affect the risk for corneal
infiltrative events. Over the past 20 years, a shift from
traditional hydrogel materials toward silicone hydrogel ma-
terials, which provide higher oxygen transmission, has
occurred.71 Silicone hydrogels may increase the risk of
corneal infiltrative events, but the broad benefits of these
lenses outweigh this risk for many patients.72
Third, age is a significant, but nonlinear, risk factor for
contact lens-related adverse events. A retrospective, obser-
vational study evaluated the risk factors that interrupt soft
contact lens wear among children, teenagers, and young
adults.57 The authors reported 187 corneal infiltrative events
in 3549 patients for 14 305 visits observing 4663 soft
contact lens years, including an average of 20 months of
soft contact lens wear in 1054 patients younger than 18
years. The corneal infiltrative events included 8 cases of
microbial keratitis, 110 cases of infiltrative keratitis, 41
contact lens peripheral ulcers, 14 contact lens-induced
acute red eyes with infiltrates, and 13 contact lens-induced
acute red eyes without infiltrates. The risk of a corneal
infiltrative event increased in a nonlinear fashion up to 21
years of age and then decreased, with the peak years at risk
from 15 to 25 years of age.
Figure 1 replots the published data on corneal infiltrative
events in terms of incidence (cases per 10 000 patient-years
of wear).57 The figure demonstrates the marked lower rate of
corneal infiltrative events in patients 8 to 12 years of age (97
per 10 000 patient-years; 95% confidence interval [CI],
31e235 per 10 000 patient-years) than in patients 13 to 173
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248e443 per 10 000 patient-years). The incidence of mi-
crobial keratitis per 10 000 patient-years varied dramatically
with age group: 0 per 10 000 patient-years (95% CI, 0e70
per 10 000 patient-years) in 8- to 12-year-olds, 15 per 10 000
patient-years (95% CI, 2e48 per 10 000 patient-years) in
13- to 17-year-olds, 33 per 10 000 patient-years (95% CI,
12e73 per 10 000 patient-years) in 18- to 25-year-olds, and
7 per 10 000 patient-years (95% CI, 0.4e37 per 10 000
patient-years) in 26- to 33-year-olds.
The low rate of corneal infiltrative events in patients 8 to
12 years of age from the above retrospective study of soft
contact lens wear is supported by prospective studies. Bul-
limore73 reviewed data from 9 prospective studies
representing 1800 patient-years of wear in 7- to 19-year-
olds. Most of the studies were at least 1 year in duration, fit
children as young as 8 years of age, and represented more
than 150 patient-years.23,74e82 Pooling data across the 9
studies, 14 corneal infiltrative events were reported repre-
senting an incidence of 78 per 10 000 patient-years (95% CI,
44e127 per 10 000 patient-years). None of the studies re-
ported any cases of microbial keratitis, giving a 95% CI of
0 to 21 per 10 000 patient-years. A subsequent retrospective
review of more than 800 patient-years of wear in children
also found no cases of microbial keratitis,83 although a
recent clinical trial of nearly 900 patient-years of wear in
children reported 1 “presumed case.”84
In summary, the incidence of corneal infiltrative events
and microbial keratitis in children 12 years of age and
youngerdin whom myopia control is likely to be ini-
tiateddis no higher than that observed in adults and may be
lower.85,86 The peak complication rate at 18 to 25 years of
age suggests that behavioral and lifestyle factors may have
a significant influence.87 For 8- to 12-year-olds, parents
are more likely to be involved in lens care. It is also possible
that young children wearing contact lenses are a preselected
group, because they are likely to wear them responsibly. If
contact lenses were worn by a higher proportion of children,
the low complication rate could conceivably increase.
Overnight Orthokeratology
Although the incidence of adverse events associated with soft
contact lenses is well established, data for overnight ortho-
keratology are scarce. Even in large-scale epidemiologic
studies, where all lens types were considered, no cases of mi-
crobial keratitis in orthokeratology wearers have been re-
ported.65 Of course, this reflects the relatively small proportion
of patients undergoing this particular treatment method, rather
than a low level of risk. Globally, orthokeratology represented
28% of all rigid contact lenses prescribed among minors
between 2005 and 2009.88 In the United States, all rigid
lenses account for approximately 10% of all contact lenses,
whereas patients 15 years of age and younger account for
only 11% of lens fits.71 Recent data suggest a steady, but
small, increase in orthokeratology fitting through 2017, but
this represents only approximately 1% of all contact lens fits,
with large geographical variations.89 Studies of the incidence
of microbial keratitis associated with contact lenses typically
accrue patients from hospitals and other tertiary care settings4
and are unlikely to identify patients whose disease is
associated with overnight orthokeratology because of limited
exposure, rather than the underlying risk. Beginning in 2001,
case series and case reports of microbial keratitis associated
with overnight orthokeratology began to appear in the
literature. The first 50 published cases were summarized in a
2005 article90 and updated with total of 123 cases 2 years
later.91
In 2008, the American Academy of Ophthalmology pub-
lished an Ophthalmic Technology Assessment on the safety of
overnight orthokeratology for myopia.28 The main source of
adverse events was 38 case reports or noncomparative case
series, representing more than 100 cases of infectious
keratitis. However, the assessment was unable to identify the
incidence of complications associated with overnight
orthokeratology, nor the risk factors for various complications.
The only comprehensive estimate of the incidence of
microbial keratitis associated with overnight orthokeratology
comes from a retrospective study, mandated and approved by
the United States Food and Drug Administration.92 Two
hundred randomly selected practitioners, stratified by
company and number of lens orders, were asked to provide
details on fitting date, patient age at fitting, and follow-up
duration for up to 50 randomly selected lens orders. The
practitioners were also asked to provide comprehensive in-
formation on any of these patients experiencing an episode of
painful red eye that required a visit to a practitioner’s office.
Patients treated by another practitioner or with fewer than 12
months of documented follow-up were mailed a question-
naire regarding months of lens wear, any adverse events, and
the name and address of the treating practitioner. Data were
submitted by 86 practitioners from 1494 unique patients.
Limiting the sample to at least 3 months of wear from 2005
onward resulted in 1317 patients (49% adults and 51%
children) representing 2599 patient-years of wear. Of the 50
episodes of painful red eye identified, 8 demonstrated a
corneal infiltrate, of which 6 were in children. Of these cases,
2 were judged to be microbial keratitis by a 5-person masked,
expert review panel and neither resulted in any long-term loss
of visual acuity. The overall incidence of microbial keratitis
was 7.7 per 10 000 patient-years (95% CI, 0.9e27.8 per
10 000 patient-years). Both cases occurred in children, giving
an incidence of 14 per 10 000 patient-years (95% CI,
1.7e50.4 per 10 000 patient-years).92 In summary, the
incidence of microbial keratitis in children wearing
overnight orthokeratology is similar to that reported for
other overnight methods in adults, notably extended wear
of soft contact lenses (Table 1).Modeling Risk of Vision Loss Associated
with Myopia Treatment
Given the above evidence, the risks of vision loss with
spectacle lenses and atropine are considered negligible, and
it is assumed that most risk associated with myopia control
will occur with contact lenses. The incidence of microbial
keratitis varies with contact lens wear, and all available
estimates have some uncertainty, as indicated by the breadth
of the CIs. Overnight orthokeratology in children carries a
Table 1. Incidence of Microbial Keratitis in Adults Associated with Daily and Regular Overnight Wear of Soft Contact Lenses
Country of Study Year No. of Cases
Incidence of Microbial Keratitis (per 10 000 Years of Wear)
Cases Leading to Vision Loss (%)Daily Wear Overnight Wear
United States59 1989 137 4.1 20.9 d
Scotland60 1999 20 2.4 d d
The Netherlands61 1999 92 3.5 20.0 5
Hong Kong62 2002 59 3.1 9.3
England63,64 2005 38 6.4/0.0 96.4/19.8 0
Australia65 2008 244 1.9/11.9 19.5/25.4 15
England66 2008 349 d d 4
d ¼ not available.
Two studies distinguish between hydrogel and silicone hydrogel soft contact lenses, so both values are shown.63,65 When available, the percentage of cases
leading to vision loss is shown. Vision loss is defined as a 2-line loss of visual acuity,64,65 20/40 or worse,66 or 20/70 or worse.61
Bullimore et al  Risks and Benefits of Myopia Controlrisk similar to other overnight methods, with the only esti-
mate being 14 per 10 000 patient-years (95% CI, 1.7e50 per
10 000 patient-years).92 Conversely, daily soft lens wear in
children seems to be at least as safe as in adults; daily
disposable lenses may mitigate the risk further.65 Thus, in
evaluating vision loss associated with contact lens wear, a
range of incidences should be considered.
The above summary of the risks associated with myopia
control expresses the data in terms of incidence. These data
must be interpreted in terms of years of visual impairment
associated with said risk. To estimate years of visual
impairment, the following assumptions were made:Figur
from1. Fifteen percent of all cases of microbial keratitis
result in visual impairment (2 lines of visual acuity
or more). This is the most conservative estimate.65
2. Each patient undergoing myopia control is exposed
to 5 years of contact lens wear during the period ofe 1. Bar graph showing the incidence of different inflammatory events involvin
Chalmers et al.57 CLARE ¼ contact lens-induced acute red eye; CLPU ¼ conmyopia control, and the risk is constant over this
time. Five years was chosen so that 1 D of control
could be reasonably anticipated.93
3. Any serious adverse event occurs during this 5-year
period of wear, at a mean age of 12 years.
4. Mean life expectancy is 82 years (https://
www.mortality.org), so each adverse event causing
immediate vision impairment results in 70 years
lived with this vision impairment.Table 2 displays the years of vision loss for 3 levels of
risk, expressed as annual incidence per 10 000 patients.
The incidence values are intended to span the range
reported in the literature from daily wear (1 per 10 000) to
overnight wear (25 per 10 000).65 For example, the
incidence of microbial keratitis with daily disposable soft
lenses could be assumed to be 1 per 10 000 patient-years
of wear.65 The incidence of vision loss resulting fromg the cornea and iris as a function of patient age. Data are replotted
tact lens peripheral ulcer.
5
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patient-years of wear, but 5 years of exposure results in a
cumulative incidence of vision loss of 0.75 per 10 000 pa-
tients (¼ 5  0.15). Finally, this vision loss is experienced
for 70 years, yielding a value of 53 years of vision loss per
10 000 patients (¼ 70  0.75). The years of vision loss are
proportionately higher for incidence values of 5 and 25 per
10 000 patient-years, the latter representing the upper limits
for overnight orthokeratology. The effect of increasing
exposure is calculated easily. For example, for 10 years of
exposure, the cumulative incidence of vision loss and the
number of years of vision loss is twice that for 5 years of
exposure. Likewise, using an incidence of 50dthe upper
95% limit for overnight orthokeratology in children92dthe
values in the final column double.
The NNH for 1 and 5 years of visual impairment are also
shown in Table 2. For example, 38 patients have to wear
contact lenses with a medium risk of microbial keratitis
(incidence, 5 per 10 000 patient-years) for 5 years to
result in 1 year of visual impairment. Likewise, 190 patients
have to wear them to result in 5 years of visual impairment.
The Potential Benefits of Myopia Control
Bullimore and Brennan94 recently summarized the benefits
of lowering levels of myopia. These include better
uncorrected and corrected visual acuity, improved vision-
related quality of life, and reduced dependence on correc-
tion. Likewise, a person with myopia is likely to consider
refractive surgery to correct their refractive error after they
reach adulthood. In this regard, the lower the level of
myopia, the higher the likelihood of minimal residual
refractive error, leading to better postoperative uncorrected
visual acuity and fewer secondary surgical enhancements.
Furthermore, postoperative visual quality is poorer in pa-
tients with higher levels of preoperative myopia.95 Finally,
higher myopia, thinner corneas, or both can make patients
poor candidates for LASIK because of the increased risk
for postoperative corneal ectasia,96 and alternative
procedures may be needed. Despite these visual and
refractive benefits of lower levels of myopia, the greatest
benefit of lower levels of myopia is a reduced risk of
blinding eye disease. The following sections briefly review
the association between level of myopia and myopic
maculopathy, cataract, retinal detachment, and glaucoma.
The reader is also referred to the recent comprehensive
review by Haarman et al.7
Myopia and the Risk of Myopic Maculopathy
A number of large population-based studies have examined
of the prevalence of myopic maculopathy in older patients.
Bullimore and Brennan94 summarized data from 5 studies
that present the prevalence as a function of level of myopia
in tabular or graphical form.97e101 Figure 2A shows the
prevalence of myopic maculopathy as a function of degree
of myopia for these 5 studies. Data are taken directly from
each publication, digitizing figures to extract values when
necessary.99,102 Where prevalence is presented with data for
ranges of myopia, the midpoint of each range is used. The6
highest level of myopia was often defined without an upper
limit, so these data are not shown. In all studies, the
prevalence of myopic maculopathy increases exponentially
at higher levels of myopia. Figure 2B replots the
prevalence of myopic maculopathy on a logarithmic scale.
This results in an apparent linear relationship, with all
studies showing a similar trajectory.
Since publication of the above data, 4 more reports of the
relationship between myopia level and the prevalence of
myopic maculopathy have been published,102e105 plus a fifth
that does not contain sufficient categories.106 All available
studies are summarized in Table 3 and represent data from
more than 10 000 myopes. The definition of myopia varies
among studies, with 2 limited to high myopia. Likewise,
the definition of myopic maculopathy varies slightly among
studies, with data for “macular complications” used from 1
study.105 Linear regression was performed on each dataset
and the results displayed in Table 3. The slope of
log(prevalence) per 1 D ranges from 0.095 to 0.271.
Taking the antilog of these slopes gives the ratio of
prevalence to 1 D, a range of 1.24 to 1.87 with a crude
average of 1.58. Expressed as a percentage, each 1 D of
myopia increases the prevalence of myopic maculopathy by
58%. Restated, controlling myopia progression such that a
patient’s refractive error is lower by 1 D should reduce the
likelihood of myopic maculopathy developing by 37% (¼
1 e 1 / 1.58). Furthermore, given the apparent constant
slope of the data in Figure 2B, this treatment benefit is
constant across a range of myopia severities. Thus,
although the overall risk of myopic maculopathy is higher
in a person with myopia of e6 D than a person with
myopia of e3 D, slowing progression by 1 D during
childhood should lower the risk by 37% in both people.
Myopia and the Risk of Other Ophthalmic
Diseases
Cataract. Myopia is associated with other eye diseases.
With respect to cataract, the association between myopia
and posterior subcapsular cataract (PSC) is the most
robust.107 A few studies have reported the prevalence of
PSC at different degrees of myopia (Table 4).108e111 The
same methodology as described in the previous section was
used to determine the relationship. The slope of log(preva-
lence) per 1 D ranges from 0.017 to 0.103. Converting to a
ratio of prevalence to diopters of myopia shows a range of
1.02 to 1.40, with a crude average of 1.21. Thus, each
1 D of myopia increases the prevalence of PSC by 21%.
Although not directly comparable, Pan et al108 reported that
each 1 D of myopia increases the odds of PSC by 1.14 in a
sample of 5474 Singaporean Malays. For cortical cataract, 3
of the studies in Table 4 show ratios of prevalence to 1 D of
between 0.96 and 1.01, whereas 1 study shows a ratio of
1.16.111 These same 4 studies show no relationship
between degree of myopia and nuclear cataract status. The
ratio of prevalence to diopters of myopia ranges from
0.95 to 0.99, with a crude average of 0.97. It is
important to note that many studies do show a relationship
between any myopia and nuclear cataract status.107
Unfortunately, this relationship is confounded by the
Table 2. Vision Loss Associated with 3 Levels of Risk of Microbial Keratitis
Variable Multiplier Low Risk Medium Risk High Risk
Annual incidence of MK 1 5 25
Annual incidence of vision loss  15% 0.15 0.75 3.75
Accumulated incidence of vision loss  5 yrs 0.75 3.75 18.75
Years of vision loss accrued  70 yrs 53 263 1312
NNH
For 1 year of vision loss 10 000/yrs vision loss 189 38 7.5
For 5 years of vision loss 5  10 000/yrs vision loss 945 189 38
MK ¼ microbial keratitis; NNH ¼ number needed to harm.
It is assumed that 15% of cases of microbial keratitis result in vision loss, exposure is 5 years, and any vision loss is experienced for 70 years after the event.
All values are per 10 000 patients.
Bullimore et al  Risks and Benefits of Myopia Controlmyopic shift associated with nuclear cataract. Studies that
have measured the ocular components find that nuclear
cataract is associated with myopia but not axial length or
its surrogates.107,108,112
Retinal Detachment. The association between retinal
detachment and myopia is well established. Although the
global incidence of retinal detachment has been estimated at
0.01% per year,113 3 case-control studies allow quantification
of the relationship between myopia level and incidence of
retinal detachment (Table 5).114e116 Other studies are listed
that have based estimates of the relationship on their cases of
retinal detachment and published estimates of the distribution
of refractive error.10,117,118 The data from the most recent
study119 were combined with recent estimates of myopia
prevalence in the United Kingdom120 to derive the
relationship. The slope of log(incidence) per 1 D ranges
from 0.096 to 0.173. Converting to a ratio of incidence to
diopters of myopia shows a range of 1.15 to 1.49, with
a crude average of 1.30. Thus, each 1 D of myopia
increases the incidence of retinal detachment by 30%.
Glaucoma. Individuals with myopia have approximately
twice the risk of open-angle glaucoma developing compared
with those without myopia. A meta-analysis of 8 large
studies estimated odds ratios of 2.46 (95% CI, 1.93e3.15)
and 1.77 (95% CI, 1.41e2.23) for myopia of more and less
than e3 D, respectively.121 Table 6 summarizes data from 5
studies that present data on the prevalence of open-angle
glaucoma for 3 or more levels of myopia.122e127 TheFigure 2. Line graphs showing the prevalence of myopic maculopathy plotted w
Brennan.94 The logarithmic scale emphasizes the similar trajectory of each dataslope of log(prevalence) per 1 D ranges from 0.045 to 0.096.
Converting to a ratio of prevalence to diopters of myopia
shows a range of 1.09 to 1.39, with a crude average of
1.20. Thus, each 1 D of myopia increases the prevalence
of open-angle glaucoma by 20%. Longer axial length is
associated independently with an increased prevalence of
open-angle glaucoma.128,129 Kuzin et al129 estimated that
each 1 mm more of axial length was associated with a
26% higher prevalence. Although the association between
degree of myopia and prevalence of open-angle glaucoma
seems robust, little or no relationship seems to exist between
myopia and rate of progression of glaucoma,130,131 although
those with higher myopia may have more severe disease and
present diagnostic challenges.Myopia and the Risk of Visual Impairment
Myopic maculopathy is associated with poorer visual acu-
ity.97,102 Vongphanit et al97 reported that 39% of 67 eyes
with myopic maculopathy showed visual impairment,
based on a definition of 20/40 or worse visual acuity.
Wong et al102 reported that among 119 study participants
identified as having myopic maculopathy, 26 (21.8%) had
visual impairment in at least 1 eye, based on the same
criterion. Finally, Gao et al99 report that visual impairment
was present in 10 participants (17.5%) based on the better
eye and using the criterion of worse than 20/60 visual
acuity. Although most of these studies, and the others inith both (A) linear and (B) logarithmic scales, replotted from Bullimore and
set, the additional risk associated with each diopter (D).
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Table 3. Summary of Studies of the Relationship between Degree of Myopia and the Prevalence of Myopic Maculopathy











Australia97  49 (66) 3583 603 (< e1 D) 0.271 1.87 þ87 e46
Beijing, China98  40 (56  10) 4319 1191 (< e0.5 D) 0.213 1.63 þ63 e39
Chinese Americans101  50 4144 1523 ( e0.5 D) 0.192 1.56 þ56 e36
Handan, China99  30 (52  12) 6409 1705 (< e0.5 D) 0.228 1.69 þ69 e41
Hisayama, Japan100  40 (63  11) 1892 1619 eyes ( 0 D) 0.199 1.58 þ58 e37
Singapore102 40 to 80 (57  10) 8716 3108 ( e0.5 D) 0.095 1.24 þ24 e20
Zhongshan, China103 40 to 70 (22  12) 96 96 ( e6 D) 0.230 1.70 þ70 e41
France105 60þ ( e0.5 D) 0.143 1.39 þ39 e28
Germany104 35 to 74 (51  10) 519 519 ( e6 D) 0.182 1.52 þ52 e34
D ¼ diopter.
Ophthalmology Volume -, Number -, Month 2021Table 3, precede the international photographic
classification and grading system for myopic
maculopathy,132 the criteria used to define myopic
maculopathy are broadly similar: category 2 (diffuse
chorioretinal atrophy), category 3 (patchy chorioretinal
atrophy), category 4 (macular atrophy), or one of the plus
features (lacquer cracks, myopic choroidal
neovascularization, and Fuchs spot). Category 1
(tessellated fundus) is not usually considered to represent
myopic maculopathy because it is not associated with
vision loss. The risk of vision loss is also dependent on
age, refractive error, and myopic maculopathy category.
Of course, any increase in the risk of visual impairment
associated with myopia will be the result of a range of
diseases including myopic maculopathy. Given that multiple
myopia-associated diseases can lead to visual impairment,
the relevant parameter is the cumulative risk of all myopia-
associated pathologic features. A few studies report visual
impairment from all causes as a function of level of
myopia.98,105,133,134 Among these, Tideman et al134
published the most comprehensive data on visual
impairment and myopia, analyzing data from 15 404
adults (mean age, 61  11 years) in whom refractive error
and visual acuity had been measured. In their Figure 2,
they plot the cumulative risk of visual impairment as a
function of age for 5 levels of myopia for a criterion of
20/67 visual acuity (0.3 decimal visual acuity equivalent).
Their graph was digitized, and the cumulative risk of
visual impairment is replotted as a function of myopia
level for 5 ages in Figure 3. The midpoint of each
refractive error range was used, and a value of e16 D
was chosen for the highest range. The data show a clear
exponential trend at all ages, a feature that is emphasizedTable 4. Summary of Studies of the Relationship between Degree o
Population Age Range (Mean), Years No. Myo
Beaver Dam, United States111 43e84 (61  11) 4470 1
Singapore Chinese110 40e79 1029
Salisbury, United States109 65e84 (73  5) 5040 eyes 736
Singapore Indian108 40e84 (59  10) 5768 1
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by plotting them on a logarithmic scale. On the
logarithmic scale, all ages follow a similar, near parallel
trajectory. The best-fit slopes of these lines (not shown)
range from 1.24 to 1.31, indicating that the cumulative
risk of visual impairment increases by between 24% and
31% per 1 D of myopia across a broad age range.
From the values in Figure 3, the odds of visual impairment
were calculated using a reference prevalence of 1.26%. This
reference was calculated from the distribution of visual acuity
among the 4 population-based cohorts used by Tideman
et al,134 excluding the case-control study (their Table 1).
Figure 4 shows the log10 odds ratio of visual impairment as
a function of age for 5 levels of myopia. Multiple linear
regression was used to estimate log10 odds ratio as a
function of age and refractive error (Rx). The equation for
best-fit regression line shown in Figure 4 is:
log10 odds ratio for visual impairment ¼
0.057age e 0.122Rx e 4.03.
Thus
cumulative odds of visual
impairment ¼
10(0.057 age e 0.122Rx e 4.03).
Note that the coefficients show that the impact of 1 D of
myopia is approximately twice that of 1 year of aging.
Using this equation, the age-related cumulative risk of
visual impairment can be modeled for different myopia
levels. Figure 5 shows the cumulative risk of visual
impairment as a function of age for 7 levels of myopia
and 2 different definitions of visual impairment. On the
left is the model for the criterion for visual impairment
used in the original data134 (worse than 20/67 or 6/20),
which is similar to the World Health Organization (WHO)












149 0.145 1.40 þ40 e28
340 0.009 1.02 þ2 e2
eyes 0.103 1.27 þ27 e21
498 0.060 1.15 þ15 e13














Japan114 1166 11 671 0.113 1.30 þ30 e23
EDCCS, United States115 253 1138 0.110 1.29 þ29 e22
China116 61 61 0.059 1.15 þ15 e13
Switzerland118 195 d 0.096 1.25 þ25 e20
England10 452 d 0.173 1.49 þ49 e33
Iowa, United States117 172 d 0.156 1.43 þ43 e30
Scotland, United Kingdom119 1202 d 0.096 1.25 þ25 e20
EDCCS ¼ Eye Disease Case-Control Study; d ¼ not available.
Bullimore et al  Risks and Benefits of Myopia Controldefinition of moderate visual impairment (worse than 20/60
or 6/18). The model on the right is for the United States
definition of visual impairment (worse than 20/40), which
is also the WHO International Classification of Diseases,
Eleventh Revision, definition of mild visual impairment.
These were calculated using the above equations for the
odds of visual impairment but using an overall prevalence
of 3.63%. This value again was calculated from the visual
acuity distribution among the 4 population-based cohorts
used by Tideman et al,134 excluding the case-control study
(their Table 1). As would be expected, both sets of curves
follow a sigmoidal pattern.
To further assess the impact of age and myopia on the
visual impairment for individuals and the population, the
above functions were combined with life expectancy data
for the United States population (https://www.mortali-
ty.org) to estimate the number of visually impaired peo-
ple per 10 000 births as a function of age and myopia. A
simple combination of the functions results is a series of
asymmetric bell curves shown in Figure 6. The peak of
the distribution shifts from 86 years for e2 D of
myopia to 81 years for e8 D of myopia and thereafter
decreases by approximately 1 year for each additional 1
D of myopia up to e15 D (not shown). The presence
of an earlier peak in those with higher myopia than in
those with lower myopia reflects the earlier onset of
myopia-related retinal complications105 than conditions
where myopia is not a risk factor and may be
protective, that is, AMD and diabetic retinopathy.125
Beyond the peak, the influence of mortality outweighs
the increased risk of visual impairment, resulting in aTable 6. Summary of Studies of the Relationship between Degree o
Population Age Range (Mean), Years No. My
India122 40e90 (51) 5150
Beijing123 40e101 (56  10) 4319
NHANES, United States124 40 and older 5277 1
Singapore Indian125 40e84 (59  10) 5768 1
South Korea126 40 and older 13 433 2
Kaiser, United States127 35 and older (58  12) 437 438
NHANES ¼ National Health and Nutrition Examination Survey; d ¼ not avsteadily decreasing probability of living with visual
impairment.
The mean number of years of visual impairment experi-
enced by a patient over their lifetime may be estimated by
simply integrating the area under each curve. For example, a
person with myopia of e3 D will experience an average of
4.42 years of visual impairment (United States definition and
WHO definition of mild visual impairment), whereas a per-
son with myopia ofe8 D will experience 9.56 years of visual
impairment. These data are summarized in Table 7.
Furthermore, the benefit of slowing myopia progression by
1 D of myopia can be calculated as the difference in years
of visual impairment (Table 7). Controlling myopia such
that a patient destined to be a person with myopia of e3 D
instead ends up as a person with myopia of e2 D should
prevent an average of 0.74 years of visual impairment
(¼ 4.42 e 3.68). Likewise, 1 D of myopia control such
that, ultimately, a person with myopia of e8 D instead is a
person with myopia of e7 D would save 1.22 years of
visual impairment (¼ 9.56 e 8.35).
Table 7 also shows the NNTdthe number slowed by 1
Ddto prevent 5 years of visual impairment. For e3 D of
myopia, the NNT is 6.75, whereas for e8 D of myopia,
the NNT is 4.11. Finally, the reduction in myopia needed
to prevent 1 year of visual impairment in a given patient
can be estimated. For e3 D of myopia, a 1.38-D reduction
is needed, but for e8 D of myopia, only a 0.82-D reduction is
required. To put these figures in context, the NNT for pre-
venting 1 nonfatal heart attack in asymptomatic adults 40
years or older with statin medications is 217, and the NNT to












d 0.032 1.08 þ8 e7
978 0.066 1.16 þ16 e14
241 0.053 1.13 þ13 e12
498 0.144 1.39 þ39 e28
986 0.082 1.21 þ21 e17
d 0.037 1.09 þ9 e8
ailable.
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Figure 3. Line graphs showing the cumulative risk of visual impairment as a function of level of myopia for 5 age ranges using (A) a linear scale and (B) a
logarithmic scale. Data are from Figure 2 of Tideman et al.134 D ¼ diopter.
Ophthalmology Volume -, Number -, Month 2021The corresponding data for the WHO definition of
moderate visual impairment are shown in Table 8. Both the
mean years of visual impairment and the years of visual
impairment prevented by a 1-D reduction in myopia are
smaller than for the United States definition. Likewise, the
NNT to prevent 1 year of visual impairment and the
reduction in myopia needed to prevent 1 year of visual
impairment are higher.Comparing the Risks and Benefits of
Myopia Control
The above model shows the potential benefit of slowing
myopia progression such that a patient ends up with 1 D less
than their original refractive trajectory. Recent randomized
clinical trials suggest that 1 D of myopia control isFigure 4. Line graph showing the log10 odds of visual impairment as a
function of level of myopia for 5 age ranges plotted a logarithmic scale.
Based on data from Tideman et al.134
10achievable given that a 0.73-D reduction in progression was
achieved with 3 years of treatment with a daily disposable
soft contact lens incorporating a dual-focus optical design,23
a 0.71-D reduction was achieved with 3 years of executive
bifocal spectacle wear,33 and a 0.82-D reduction was ach-
ieved with 2 years of 1% atropine therapy.46 Although few
studies have reported myopia control on patients beyond 3
years,136,137 the above results suggest that 1 D is feasible
but would take up to 5 years of treatment.93
The above model predicts that 1 D of myopia control can
prevent between 0.74 and 1.22 years (9e15 months) of
visual impairment for myopia levels of between e3 and e8
D. Referring back to the years of visual impairment that may
be associated with 5 years of contact lens wear (Table 2), the
range corresponding to the published range of incidence
levels of microbial keratitis is between 53 and 1312 years
of visual impairment per 10 000 patients. This represents
a range of 0.0053 to 0.1312 years per patient. This leads
to the reasonable conclusion that the benefits of myopia
control far outweigh the risks of the 5 years of contact
lens wear required to achieve this 1 D of control. Another
way to compare risk and benefit is using NNH and NNT.
For the range of values in Table 2, the NNH for 5 years
of visual impairment is between 38 and 945. That is, even
for the highest incidence of microbial keratitis (25 per
10 000 years), 38 patients would need to be exposed to
induce 5 years of visual impairment. In contrast, only 4.11
to 6.75 patients would need to have their ultimate myopia
level reduced by 1 D to prevent 5 years of visual
impairment. For the level of risk that may be expected for
myopia control using daily disposable contact lenses (1
per 10 000 years), the NNH outweighs the NNT by a ratio
of 140 for a person with e3 D of myopia (¼ 945 / 6.75)
and 230 for a person with e8 D of myopia (¼ 945 /
4.11). Thus, for therapies that carry low risk, the benefits
are compelling, but for smaller amounts of myopia control
or higher levels of risk, the benefits are still meaningful.
For example, slowing myopia by 0.50 Ddequivalent to
slowing axial elongation by 0.18 mm138dstill lowers the
Figure 5. Line graphs showing the model of visual impairment as a function of age (years) for different levels of myopia and 2 different definitions of visual
impairment. The left panel is (worse than 20/67 or 6/20),134 which is similar to the World Health Organization (WHO) International Classification of
Diseases, Eleventh Revision, definition of moderate visual impairment (worse than 20/60 or 6/18), whereas the right panel is for the United States
definition (worse than 20/40), which is also the WHO International Classification of Diseases, Eleventh Revision, definition of mild visual impairment.
D ¼ diopter.
Bullimore et al  Risks and Benefits of Myopia Controlrisk of myopic maculopathy by 20% and, on average,
prevents 6 months of visual impairment.
This comparison reflects conservative estimates of the
total treatment benefit from myopia control derived from
current methods of management.93 The benefits would scale
up if a greater level of myopia control could be achieved,
especially for those with higher myopia. For example, the
data in Table 7 can be used to calculate the benefit of 2 D
of control in a patient destined to have myopia of e7 D
(8.35 e 6.19 ¼ 2.16 years of visual impairment) or a
benefit of 3 D of slowing in a patient who would
otherwise have e6 D of myopia (7.22 e 4.42 ¼ 2.8 years
of visual impairment).
An important consideration is that values for visual
impairment associated with myopia are for bilateral
impairment (Tables 7 and 8), whereas the estimates of vision
loss associated with contact lens wear in Table 2 are
monocular and correspond to rates based on 2 lines ofFigure 6. By combining the risk of visual impairment as a function of age for diff
with visual impairment (VI) can be determined. The mean number of years
estimated by integrating the area under each curve.loss of visual acuity.65 Bilateral cases of contact lens-
related microbial keratitis are rare. For example, among
the 367 cases reported by Dart et al,66 only 1 case was
bilateral. Even in large case series of acanthamoeba
keratitis, bilateral infection occurred in only 5 of 183
patients139 and 3 of 154 patients.140 Furthermore, although
some patients with vision loss resulting from contact lens-
associated infections require corneal transplantation, pa-
tients with less severe cases may experience amelioration
with rigid contact lenses or phototherapeutic keratec-
tomy.141,142 In summary, the binocular visual impairment
associated with contact lenses is far lower than the
binocular visual impairment associated with each
additional 1 D of myopia. Of course, a patient who has
reduced vision in 1 eye is then at greater risk of bilateral
visual impairment throughout the rest of their life as a
result of other causes,143 and the loss of binocularity
could impact future career choices and quality of life.erent levels of myopia with mortality data, the probability of a patient living
of visual impairment experienced by a patient over their lifetime may be
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Table 7. Mean Lifetime Years of Visual Impairment as a Function of Level of Myopia Using the United States Definition of 20/40, Which










Treat to Prevent 5 Years
of Visual Impairment
Reduction Needed to
Prevent 1 Year of Visual Impairment (D)
e3 4.42 0.74 6.75 1.38
e4 5.25 0.84 5.97 1.22
e5 6.19 0.93 5.35 1.07
e6 7.22 1.03 4.85 0.97
e7 8.35 1.13 4.44 0.88
e8 9.56 1.22 4.11 0.82
D ¼ diopter.
Also shown are mean years of visual impairment prevented by a 1-D reduction in a patient’s ultimate level of myopia, the number of patients needed to treat
to prevent 5 years of visual impairment, and the reduction in myopia needed to prevent 1 year of visual impairment.
Ophthalmology Volume -, Number -, Month 2021Limitations of Model
A number of assumptions are required to produce a risk-to-
benefit model for myopia control, and the accuracy of such a
model is dependent on the validity of these assumptions.
Our model of visual impairment and myopia uses some
interpolation regarding age because only data through 75
years were available. It is possible that the relationship be-
tween myopia and visual impairment is different at older
ages; for example, the prevalence of AMD is lower in
people with myopia.125 The rising worldwide prevalence of
myopia is leading to secular trends. A large population-
based Japanese study reported that the age-adjusted preva-
lence of myopic maculopathy doubled in 1 decade.8
Likewise, a 44% increase in the incidence of retinal
detachment in The Netherlands has been documented over
a 7-year period that the authors attribute to myopia,
although this is a small contributor to visual impairment.144
A similar increase was previously reported in Scotland.145
The inclusion of both age and myopia level in the model
of visual impairment should make it relatively robust
moving forward.
The assessment of vision loss associated with contact
lens wear assumes that the risk is constant over time and



















D ¼ diopter; d ¼ not available.
Also shown are mean years of visual impairment prevented by a 1-D reduction in
to prevent 5 years of visual impairment, and the reduction in myopia needed t
12Figure 1, the incidence of contact lens-related adverse
events increases as children become teenagers,57
presumably because of engaging in behavior likely to
increase the risk of adverse events.87 Likewise, those with
higher myopia are more likely to engage in risky behavior
related to their contact lenses.146,147 A value of 15% for
the proportion of cases of microbial keratitis was chosen
based on the 2-line loss of visual acuity.64,65 Other studies
have reported rates of 4% for a criterion of 20/40 or
worse visual acuity66 and 5% based on 20/70 or worse
visual acuity.61 The calculations in Table 2 are all linear,
so the effect of replacing 0.15 with a different value is
easily calculated. Our model of visual impairment
associated with contact lenses assumes that the design of
the lens does not play a role and that the increased risk is
the result of increased exposure. Intuitively, those
additional years of wear would occur when the child is
younger and their myopia relatively low.
The current model assumes a fixed treatment effect with
myopia control. Although the efficacy of these technologies
shows a reduction in subsequent years of treatment,93 a
more sophisticated model or simulation could explore
variations in treatment duration, treatment effect, or both.
The model also uses data from only 1 article reporting
predominantly White Europeans, although a recent clinic-vel of Myopia Using the World Health Organization Definition of
pairment, 20/60
o. Needed to Treat
o Prevent 5 Years
Visual Impairment
Reduction Needed







a patient’s ultimate level of myopia, the number of patients needed to treat
o prevent 1 year of visual impairment.
Bullimore et al  Risks and Benefits of Myopia Controlbased French study of nearly 200 000 myopic adults shows
a similar relationship between myopia level and visual
impairment.105 Both studies include all causes of visual
impairment and thus account for age-related increases in
AMD and the potentially protective effect of myopia. It will
be important to extend these results to other populations as
data become available, particularly Asians, in whom the
prevalence of myopia is higher. It should be noted that the
prevalence of visual impairment in this Dutch population148
is lower than in other comparable populations.149,150
Recent comprehensive reviews of the efficacy of myopia
control are available,17,93,151 but long-term data on myopia
control and whether the benefits are sustained are scarce.
Few published studies are longer than 3 years’ duration. Of
the 26 studies considered by Brennan et al,93 only 4 exceed
2 years and most reports in the literature are 1 year in
duration. Likewise, few studies demonstrate more than 1
D of treatment effect,136,137,152 and caution must be
exercised when extrapolating the findings of shorter-
duration trials, because slowing of progression in the first
year of treatment is greater than in subsequent years.93
Nonetheless, a recent report of the only Food and Drug
Administration-approved myopia control device demon-
strates a 6-year 0.53-mm slowing of axial elongation, which
in dioptric terms approaches 1.50 D.152
The extent to which benefits are sustained after treatment
is withdrawn is not settled. Dramatic posttreatment acceler-
ation, or rebound, has been reported with 1% atropine but
does not seem to occur with spectacle lens35 or soft contact
lens75,153 therapies. Nonetheless, some level of rebound
should be assumed until proven otherwise.93 The choice of
treatment will ultimately be determined by a discussion
among practitioner, parent, and patient but will be
influenced by regional practice patterns and scope of practice.
The use of NNTs and their comparison with NNH is not
beyond reproach.154e156 Numbers needed to treat vary with
baseline or event rate, and an NNT without the treatment
period and follow-up period is difficult to interpret. For these
reasons, a range of rates of visual impairment was explored,
with care to specify the duration of treatment and calculate
years living with any impairment. Comparisons between
different outcomes, for example, risks of microbial keratitis in
contact lens wear with risk of vision impairment resulting
from increasing myopia, could also be criticized.157 In
contrast, the analyses express both NNH and NNT in a
single metric: years of visual impairment. A further valid
criticism of the presentation of NNH and NNT is the
absence of CIs. The naïve approach to calculating a CI for
NNT is by inverting the limits for ARR, but this does not
yield a valid CI. Our approach has been to explore a range
of underlying assumptions and present data for a range of
risks and benefits. Finally, the analysis assumes that all
years of visual impairment are created equal, which may or
may not be valid. For example, visual impairment earlier in
life may impact earning potential, and comparing this with
later-onset visual impairment when comorbidities may exist
is a complex problem.158
Finally, this is not a cost-benefit analysis, and future work
should consider the cost associated with myopia control,
including those associated with adverse events, along thepotential savings associated with any reduction in ocular
morbidity. Nonetheless, some brief comment is warranted.
First, few attempts have been made to estimate the costs of
visual impairment. Frick et al159 used Medical Expenditure
Panel Survey data to estimate the effect of visual impairment
with total medical expenditures, components of
expenditures, days of informal care received (direct costs),
and health utility (indirect costs) among patients 40 years of
age and older in the United States. The direct costs of visual
impairment (individual excess medical expenditures) were
estimated to be $1037 (for 2004). Adjusted for 2021, this is
$1446. For indirect costs, Frick et al assumed that visual
impairment corresponds to a loss of 0.05 quality-adjusted life
years (QALYs) and used a “common but arbitrary value for a
QALY in the [United States] of $50 000,” resulting in
$2500,160 which adjusted for 2020 gives $3779. Frick et al
acknowledge that their estimate of the economic impact is
limited because it does not include productivity loss.159
Furthermore, all estimates can vary dramatically with the
underlying assumptions. For example, other authors apply an
upper limit of $100 000 per QALY and consider the
difference between 20/20 and 20/40 to represent 0.12
QALYs.158
The costs associated with myopia control are also chal-
lenging to estimate. At the time of writing, only 1 device or
drug is Food and Drug Administration-approved for myopia
control in the United States and was launched only in the
past year, although it has been available in other countries
for some years. Analyses need to include costs of drugs or
lenses, but these are incremental because the child will
already be wearing spectacles or contact lenses. The cost of
additional office visits and measurements, including axial
length, also need to be incorporated. All these costs vary
across countries.
The cost to families of myopia control when that treat-
ment is generally not covered by vision or medical insurance
may mean that the prevention or slowing of myopia to
reduce the risk of visual impairment later in life may be at
the expense of other medical conditions, such as oral
care.161 This can potentially exacerbate health disparities in
underserved communities, as highlighted in a recent Prevent
Blindness report, particularly minority communities.162 The
supplemental material in the recently published report of the
American Academy of Ophthalmology Task Force on
Myopia163 includes a number of goals, including the
following: “Encouraging government and commercial
insurers to cover myopia control as part of their medical
and vision benefits would further expand the interventions
available to clinicians and might allay future vision loss
and costs associated with higher degrees of myopia.
Health disparities in myopic minority children in the
United States are likely to be amplified unless insurance
coverage for myopia treatments is expanded.” We believe
that all stakeholders should consider this issue.
Finally, those at the greatest risk of maculopathy and
visual impairment developing are those with higher levels of
myopia.134 Likewise, our model shows that the greatest
individual reductions in visual impairment resulting from
myopia control are accrued in those with higher myopia.
Given the strong relationship between age of onset and13
Ophthalmology Volume -, Number -, Month 2021ultimate severity of myopia,2,4 it is most important to direct
efforts at those children who demonstrate myopia relatively
early in life. As Brennan et al93 recently stated, “Because of
the risks of complications later in life and our current
inability to predict with great accuracy those who go on to
higher degrees of myopia, this leads us to recommend that
all young myopes (say 12 years of age and below)
deserve to be treated.”
One question that is currently unresolvable is whether
the observed associations of refractive error and ocular
disease are directly causal and whether a reduction in
myopia with treatment will reduce the associated risks.
Because of the 40-year or more delay between myopia
treatment and the increased risk of vision loss, this is a
challenging question to address. One suggestion for why a
causal relationship exists is the increasing prevalence of
myopic maculopathy associated vision loss in countries
that have experienced the most rapid increases in myopia
prevalence and severity such as China, where myopic
maculopathy has risen to become the leading cause of
vision impairment.14,164 Myopic maculopathy is also the14leading cause of uncorrectable visual impairment among
Chinese Americans.165
In summary, we have reviewed the risks associated with
various myopia control therapies, particularly contact lenses,
and the predicted visual loss resulting from 5 years for
therapy. We have examined the increased risk of ocular
disease associated with increasing levels of myopia and, more
importantly, the relationship between visual impairment and
myopia level. Finally, we compared the potential benefits of
reducing a patient’s ultimate level of myopia by 1 D. Our
model suggests that the potential benefits of myopia control
outweigh the risks: the NNT to prevent 5 years of visual
impairment is between 4.1 and 6.8, whereas fewer than 1 in
38 will experience the same loss of vision as a result of
myopia control.
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